Flambeau Diagnostics LLC
Flambeau RapidX is a pioneering company in mobile lab diagnostics, developed in response to the NIH RADx initiative. They offer high-performance, same-day mobile diagnostic testing solutions designed to bridge gaps in testing capacity, especially in underserved and rural areas. Their innovative platform integrates microengineering, robotics, and molecular biology to deliver rapid, accurate, high-throughput testing with adaptability for multiple diseases.
Industries
Nr. of Employees
small (1-50)
Products
Mobile contained high-throughput laboratory system
A fully contained mobile laboratory platform integrating automated sample preparation, nucleic acid amplification workflows, robotics, liquid handling, plate reading and data systems to deliver same-day molecular diagnostic results.
Mobile contained high-throughput laboratory system
A fully contained mobile laboratory platform integrating automated sample preparation, nucleic acid amplification workflows, robotics, liquid handling, plate reading and data systems to deliver same-day molecular diagnostic results.
Services
Deployment and operation of mobile laboratory units that perform same-day molecular diagnostic testing at customer sites.
Deployment and operation of mobile laboratory units that perform same-day molecular diagnostic testing at customer sites.
Expertise Areas
- Mobile diagnostic laboratory deployment
- High-throughput molecular diagnostics
- Assay automation and robotics integration
- Sample preparation and analyte extraction
Key Technologies
- RT-LAMP nucleic acid amplification
- PCR-level analytical sensitivity
- Collaborative robotics
- Automated liquid handling
News & Updates
Flambeau RapidX was one of 25 companies out of 716 to win major contracts under the NIH RADx Tech initiative, a $500M federal program for COVID-19 testing.
Developed a category-defining mobile diagnostic system that provides high performance testing with same-day results, integrating microengineering, robotics, and molecular biology.
Flambeau RapidX was one of 25 companies out of 716 to win major contracts under the NIH RADx Tech initiative, a $500M federal program for COVID-19 testing.
Developed a category-defining mobile diagnostic system that provides high performance testing with same-day results, integrating microengineering, robotics, and molecular biology.